Protocol ALK8700 -A301, Version 5.[ADDRESS_309011]
Maidenhead, Berkshire 
SL64AY
[LOCATION_008]
For urgent medical issues in which the stud y Medical Director should be contact[INVESTIGATOR_530], please refer 
to the Study  Reference Manual’s Official Study  Contact L ist for complete contact [CONTACT_3031].
Biogen may  transfer any  or all of its study -related responsibilities to a contract research 
organization and other third parties; however, Biogen retains overall accountability  for these 
activities.
Protocol ALK8700 -A301, Version 5.[ADDRESS_309012] OF ABBREVIATION S
.....................................................................................19
3. INTRODUCTION ......................................................................................................21
3.1. Study  Rationale ...........................................................................................................21
3.1.1. Rationale for Study  Population ...................................................................................21
3.1.2. Rationale for Dosing Regimen ...................................................................................21
3.2. Background .................................................................................................................22
3.2.1.
Overview of Multiple Sclerosis..................................................................................22
3.2.2.
Current Therapi[INVESTIGATOR_254090] ...................................................................22
3.2.3. Profile of Previous Experience With AL KS 8700 ......................................................23
[IP_ADDRESS]. Clinical Studies ...........................................................................................................23
[IP_ADDRESS].
Nonclinical Studies.....................................................................................................24
3.3. Benefit -Risk Assessment ............................................................................................25
4. STUDY OBJECTIVES AND ENDPOINTS
..............................................................26
5. STUDY DESIGN .......................................................................................................27
5.1. Study  Overview ..........................................................................................................27
5.2. Study  Duration for Subjects ........................................................................................27
5.3. Study  treatment Dose Adjustment and Stoppi[INVESTIGATOR_1869] ..............................................28
5.4. Unscheduled Visits ................................ ................................ ................................ .....28
5.5. Follow -up................................ ................................ ................................ .................... 29
5.6. End of Study ................................ ................................ ................................ ............... 29
6. STUDY POPUL ATION................................ ................................ ............................. 30
6.1. Inclusi on Criteria ........................................................................................................30
6.1.1.
Rollover Subjects................................ ................................ ................................ ........ 30
6.1.2. De Novo Subjects ................................ ................................ ................................ .......30
6.2. Exclusion Criteria ................................ ................................ ................................ .......31
6.2.1. Rollover Subjects................................ ................................ ................................ ........ 31
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
56.2.2. De Novo Subjects .......................................................................................................31
6.3. Screening, Retesting, and Screen Failures ..................................................................33
6.3.1. Screening ....................................................................................................................33
6.3.2. Retesting .....................................................................................................................33
6.3.3. Screen Failures ............................................................................................................34
7. STUDY TREATMENT ..............................................................................................35
7.1. Regimen ......................................................................................................................35
7.2. Modification of Dose and/or Treatment Schedule ......................................................35
7.2.1. Rescue .........................................................................................................................36
7.2.2. Relapse ........................................................................................................................36
7.3. Study  Treatment Management ....................................................................................37
7.3.1. ALKS 8700
.................................................................................................................38
[IP_ADDRESS].
Packaging and Labeling..............................................................................................38
[IP_ADDRESS]. Storage ........................................................................................................................38
[IP_ADDRESS]. Handling and Disposal ................................................................................................38
[IP_ADDRESS]. Accountability .............................................................................................................38
7.4. Blinding Proced ures....................................................................................................38
7.5. Precautions ..................................................................................................................39
7.6. Compliance .................................................................................................................39
7.7. Concomitant Therap y and Procedures ........................................................................39
7.7.1. Concomitant Therap y
.................................................................................................39
[IP_ADDRESS]. Allowed Concomitant Therap y...................................................................................39
[IP_ADDRESS]. Disallowed Concomitant Therap y
..............................................................................[ADDRESS_309013] to Follow
-Up................................ ................................ ................................ .......41
8.3. Withdrawal of Subjects From the Study .....................................................................42
9. EFFI CACY AND PHARMAC OKINETIC ASSESSMENTS ...................................44
9.1. Clinical Efficacy  Assessments ....................................................................................44
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
644
9.1.2. Structured Interviews and Questionnaires ................................ ................................ ..45
[IP_ADDRESS]. Expanded Disability  Status Scale ...............................................................................45
[IP_ADDRESS].
EuroQol Group Health Outcome Measure (5 level; EQ-5D- 5L) ...............................46
9.1.3.
Timed 25-Foot Walk...................................................................................................46
[IP_ADDRESS]. Short Form 12 Health Survey .....................................................................................46
[IP_ADDRESS]. Columbia -
Suicide Severity  Rating Scale ....................................................................[ADDRESS_309014]
ive Procedures or Routinely  Scheduled Treatments ................52
11.2. Safety  Classifications ..................................................................................................52
11.2.1. Investigator Assessment of Events .............................................................................52
11.2.2. Relationship of Even ts to Study  Treatment ................................................................52
11.2.3. Severity  of Events .......................................................................................................54
11.2.4. Expectedness of Events ..............................................................................................54
11.3. Monitoring and Recording Events ..............................................................................54
11.3.1. Adverse Events ................................ ................................ ................................ ........... 54
11.3.2. Serious Adverse Events ................................ ................................ .............................. 55
11.3.3. Immediate Reporting of Serious Adverse Events.......................................................55
[IP_ADDRESS]. Deaths ................................ ................................ ................................ ......................... [ADDRESS_309015] OF TABLES
Table 1: Schedule of Assessments ............................................................................................14
Table 2:
Additional Follow- Up for Subjects With Ly mphopenia ............................................18
Table 3: Clinical L aboratory  Assessments ...............................................................................[ADDRESS_309016] OF FIGURES
Figure 1: Study  Design Schema tic.............................................................................................13
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
91. KEY STUDY ELEMENTS
1.1. Synopsis
Protocol Title : A Phase 3 Open Label Study  to Evaluate the Long-T erm Safety  
and Tolerabilit y of ALK S 8700 in Adults W ith Relapsing 
Remitting Multiple Sclerosis
Protocol Number : ALK8700 -A301
Version Number : 5.0
Name [CONTACT_254125] :ALK S 8700 (also known as BIIB098 and diroximel fumarate)
Study  Phase : 3
Study  Indication : Multiple sclerosis (MS)
Study  Rationale : Disease -modify ing therapi[INVESTIGATOR_254091], prevent disability ,and improve quality  of 
life. The ALKS [ADDRESS_309017] is a modified-release oral 
dosage form that provides a monomethy l fumarate (MMF) 
exposure profile that may  limit gastrointestinal (GI) effects 
associated with dimeth yl fumarate (DMF) treatment while 
maintaining efficacy  comparable to that demonstrated with 
DMF. Accordingl y, ALKS 8700 has the potential to address an 
unmet medical need for patients with relapsing forms of MS who 
are unable to tolerate DMF, particularly  due to GI effects.
Rationale for Dose and 
Schedule Selection:Unless otherwise specified all doses referred to are administered 
twice dail y (BID). The selected dose level of ALKS 8700 
delay ed release (DR; 462 mg) is supported b y clinical safet y, 
tolerability , and 
pharmacokinetic ( PK)data from prior clinical 
studies. The doses of ALKS 8700 to be used for initial dose 
titration (231 mg) and for treatment maintenance (462 mg) in this 
study  are within the range of doses evaluated i n a completed 
single ascending dose study  and in a completed repeat dose 
clinical study . Safet y data from both studies indicate that doses 
of 210 mg, 420 mg,and 630 mg (231mg and 462 mgdoses to be 
used in this study ), administered either as a single dos e or BID
for 5days in healthy  volunteers were generally  well tolerated 
with no relevant differences in safet y or tolerability between 
single or repeat dosing at each dose level. In addition, it was 
Protocol ALK8700 -A301, Version 5.[ADDRESS_309018] s who meet the 
following criteria:
Male and female adults aged 18 to 65 years, inclusive, 
at Screening
Has a confirmed diagnosis of RRMS according to the 
revised 2010 McDonald criteria
EDSS score of 0.0- 6.0 at screening and Visit 2
Neurologicall y stable wi th no evidence of relapse 
within [ADDRESS_309019] swho meet the 
following criterion :
Completed the full treatment period of an y eligible 
study  of ALKS [ADDRESS_309020] s:Approximately  [ADDRESS_309021] swill be dosed .
Treatment Groups: Study  treatment
includes ALKS [ADDRESS_309022] dose of ALKS 8700 at Visit 2 (Day 1). From 
that point on during the treatment period, the staff will dispense 
ALKS 8700 for 
participation s’ self -administration. Subject s will 
be instructed to take study  treatment with or without food. 
However, subject s will be instructed to avoid taking study  
treatment with a high- fat, high -calorie meal.
Sample Size 
Determination:No formal sample size calculation is performed for this study . A 
sample size of approximately  [ADDRESS_309023] s with 
RRMS, taking into account I nternational Council for 
Harmonisation guidance on the extent of patient exposures 
required to assess clinical safet y for a new drug.
Visit Schedule : Subject s will have up to 16 visits during the study. 
Study  assessments conducted at each visit are listed in the
Schedule of Activities ( Table 1).
Duration of 
Study  
Participation:Study  duration for each subject will be approximately  
102weeks:
4-week screening period (De Novo Subject s onl y)
96-week treatment period
2-week follow -up period
Benefit -Risk Analy sis: The potentia l risks related to participation in this study  are 
justified by  [CONTACT_254101] s.
The modified -release oral dosage form may  provide an MMF 
exposure profile that may  limit GI  effects associated with DMF 
treatment while maintaining efficac y. Accordingly, ALKS 8700 
has the potential to address an unmet medical need for patients 
with relapsing forms of MS who are unable to tolerate DMF.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
131.2. Study Design Schematic
Figure 1: Study Design Schematic
*Dosing is twice daily.
De Novo Subject s and Rollover Subject s defined in Section 5.1.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
141.3. Schedule of Activities
Table 1: Schedule of Assessments
Screening 96-Week -Open -Label Treatment1
Visit 1223TC43 TC44 5 6 7 8 9 10 11 12 13 14 15/E
T16 
Follow -
Up
Day -28 to -1 1 8
(±2)15
(±3)22
(±2)29
(±3)57
(±5)85
(±5)113
(±5)141
(±5)169
(±5)253
(±5)337
(±5)421
(±5)505
(±5)589
(±5)673
(±5)687
(±5)
Week -4 to -1 1 2 4 8 12 16 20 24 36 48 60 72 84 96 98
Informed 
consent5X
Eligibility 
Criteria 
Revie wX X6
Dem ographics 
and Medical 
HistoryX
Physical 
Examination7X X7X X X X X X X X X X X X X X
Height8X
Weight X X6X X X X X X X X X X X
Urine 
Pregnancy 
TestX X6X X X X X X X X X X X X
Serology 
Testing8X
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MA Inc.
15Screening 96-Week -Open -Label Treatment1
Visit 1223TC43 TC44 5 6 7 8 9 10 11 12 13 14 15/E
T16 
Follow -
Up
Day -28 to -1 1 8
(±2)15
(±3)22
(±2)29
(±3)57
(±5)85
(±5)113
(±5)141
(±5)169
(±5)253
(±5)337
(±5)421
(±5)505
(±5)589
(±5)673
(±5)687
(±5)
Week -[ADDRESS_309024] 
12-Lead ECGX
X6X X X X X X X X X X
PK sampling11X6X X X
Timed 25 -Foot 
WalkX X6X X X X X X X X
EDSS X X6X X X X X X X X
SF-12 X6X X X X
EQ-5D-5L X6X X X X
C-SSRS15X X6X X X X X X X X X X X X X X
Concomitant 
Medication 
Revie wX X X4X X4X X X X X X X X X X X X X
AE 
Monitoring X X X4X X4X X X X X X X X X X X X X

Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MA Inc.
16Screening 96-Week -Open -Label Treatment1
Visit 1223TC43 TC44 5 6 7 8 9 10 11 12 13 14 15/E
T16 
Follow -
Up
Day -28 to -1 1 8
(±2)15
(±3)22
(±2)29
(±3)57
(±5)85
(±5)113
(±5)141
(±5)169
(±5)253
(±5)337
(±5)421
(±5)505
(±5)589
(±5)673
(±5)687
(±5)
Week -4 to -1 1 2 4 8 12 16 20 24 36 48 60 72 84 96 98
Study 
treatment
DispensationX X X X X X X X X X X X X
Study 
treatment
AccountabilityX X X X X X X X X X X X X
Emergency 
Treatment 
Card16X X X X X X X X X X X X X X
AE = adverse event; C -SSRS = Columbia -Suicide Severity Rating Scale; ECG = electrocardiogram; EDSS = Expanded Disability Status Scale; 
EQ-5D-5L=EuroQoL Group health outcome measure 5 -level version; ET = early termination;  
; PK = pharmacokinetic; SF -12=12-item Short Form Health Survey; TC = telephone call.
Unscheduled visit may occur at any time as per protocol requirements.
2Only De Novo Subject s will participate in the Screening Visit.
3For Rollover Subject s, identical assessments taken at the last treatment visit in the antecedent study do not need to be repeated at Visit 2 in t he current study.
4Safety and tolerability assessments (in cluding AEs and concomitant medications) will be conducted by [CONTACT_254102].
5Eligible, consenting De Novo Subject s will give written consent at screening. Eligible, consenting Rollover Subject s will give written consent prior to 
participating i n any study -specific procedures at Visit 2. Written confirmation of a subject 's willingness to continue in the study will be required if one or more of 
the following occur during the study: MS relapse, disability progression,  
6To be conducted predose at Visit 2.
7Full physical examination at screening. Brief physical examination, symptom -directed, at all other visits.
8For Rollover Subject s, height will be carried over from information recorded in the antecedent ALKS 8 700 study in which they participated.
8Serology testing includes hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus antibody.
9Urinalysis includes urine dipstick, urine microscopy (as applicable), urine beta -
2-microglobul in, urine albumin, and urine creatinine.
10Vital signs measurements include temperature, respi[INVESTIGATOR_697], blood pressure, and heart rate. Blood pressure, respi[INVESTIGATOR_696] r ate, and heart rate w ill be measured 
after the subject has been in a seated or supi[INVESTIGATOR_050] p osition for at least 5 minutes.

Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MA Inc.
18Table 2: Additional Follow -Up for Subject s With Lymphopenia
AssessmentsLM Visits1
LM Visit 1
(2months after Safety 
Follow -Up Visit ± 7days)LM Visit 2
(4months after Safety 
Follow -Up Visit ± 7days)LM Visit 3
(6months after Safety 
Follow -Up Visit ± 7days)
Lymphocyte Count X X X
Concomitant Medication X X X
LM = lymphocyte monitoring.
1Subject s who complete the study or who terminate the study early and have a last measured lymphocyte co unt < 0.8x103/μL will return to the clinic for 
additional LMvisits every 2 months starting from Visit 16 for a period of 6 months (i.e., a maximum of 3 visits) or until lymphocyte count s reach normal limits 
(≥0.91 x 103/μL), whichever occurs first. All assessments req uired for the Safety Follow -Up Visit (Visit 16 , Table 1) should be completed for these subject s 
prior to initiation of the lymphocyte monitoring visits. 
Protocol ALK8700 -A301, Version 5.[ADDRESS_309025] delay ed release
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
EDSS Expanded Disability  Status Scale
EQ-5D- 5L EuroQol Group health outcome measure (5 -level)
ET early termination
FAS full analy sis set
FS functional sy stem
GCP Good Clinical Practice
GdE gadolinium -enhancing
GI gastrointestinal
GMP Good Manufacturing Practice
HDPE high density polyethylene
hERG human ether -à-go-go-related gene
HIV human immunodeficiency virus
ICF informed consen t form
ICH International Council for Harmonisation 
IRB institutional review board
IFN interferon
IRT interactive response technology
IV intravenous
LM lymphocy te monitoring
MMF monomethy l fumarate

Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and To lerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
20MS multiple sclero sis
NEDA No Evidence of Disease Activity
PK pharmacokinetic(s)
PML progressive multifocal leukoencephalopath y
RRMS relapsing -remitting multiple sclerosis
SAE serious adverse event
SF-[ADDRESS_309026] upper limit of normal
VAS Visual Analog Scale
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and To lerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
213. INTRODUCTION
3.1. Study Rationale
3.1.1. Rationale for Study Population
The m ajority  of patients with multiple sclerosis ( MS)initially  have a form known as 
relapsing -remitting MS (RRMS). Early  and effective treatment is necessary  to improve qualit y of 
life and to reduce the risk of patients developi[INVESTIGATOR_254092].
3.1.2. Rationale for Dosing Regimen
The selected dose level of ALKS 8700 DR (462 mg) is supported b y clinical safet y, tolerability, 
and PK data from prior clinical studies (Study  ALK8700 -001, ALK8700- A102, 
ALK8700 -A103, and ALK8700- A104). All doses referred to in this section are twice dail y 
(BID).
The doses of ALKS 8700 to be used for initial dose titration (231 mg) and for treatment 
maintenance (462 mg) in this study  are within the range of doses evaluated in a com pleted single 
ascending dose stud y (Study  ALK8700- 001) and in a completed repeat dose clinical study  
(Study  ALK8700 -A102). Safety  data from both studies (Study  ALK8700 -001 and 
ALK8700 -A102) indicate that doses of 210 mg, 420 mg ,and 630 mg ( 231mg and 462 mgdoses 
to be used in this study ), administered either as a single dose or BIDfor 5days in healthy  
subject s were generall y well tolerated with no relevant differences in safety or tolerability  
between single or repeat dosing at each dose level. I n addit ion, from Study  ALK8700- A102, it 
was demonstrated that the incidence of flushing with AL KS 8700 DR was lower in the fed 
condition (37.5% of subject s) compared to the fasted condition (50.0% of subject s).
The appropriateness of a maintenance [ADDRESS_309027] was confirmed b y 
2relative bioavailabilit y studies (Study  ALK8700 -A103 and ALK8700 -A104) in which PK 
results show edthat ALKS 8700 462 mg results in comparable monomethy l fumarate (
MMF )
exposure to dimethy l fumarate ( DMF )240 mg under fasted conditions, as well as in the presence 
of a high -fat, high -calorie meal. MMF exposure following administration of ALKS 8700 
provides comparable exposure to DMF in the fasted condition (Study  ALK8700- A103) and met 
the PK criteria for bioequivalence to DMF f or area under the concentration -time curve (AUC )
andmaximum observed concentration (Cmax). While total sy stemic exposure to MMF was 
comparable between ALKS 8700 and DMF in the presence of a high -fat, high -calorie meal, C max
was 26% lower (ALK8700 -A104). I n a subsequent study  (ALK8700 -A109), it was found that 
medium -fat, medium -calorie and low -fat, low -calorie meals resulted in reductions in C maxthat 
were no greater than that observed with DMF when co -administered with a high -fat, high -calorie 
meal. Theref ore, ALKS [ADDRESS_309028] s will be 
instructed to avoid taking study  treatment with a high- fat, high -calorie meal. Administration with 
food may  reduce the incidence of flushing (as observed in Study  ALK8700 -A102).
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and To lerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
223.2. Background
3.2.1. Overview of Multiple Sclerosis
MSis a chronic, debilitating disease of the central nervous s ystem that currently  affects 
approximately  2.5 million people worldwide with 5 to 10 new cases per 100,000 people each 
year[Ropper 2012; Tremlett 2010 ].
3.2.2. Current Therapi[INVESTIGATOR_254093]. Disease -modify ing therapi[INVESTIGATOR_014] (DMTs) are widely  used for the treatment of relapsing 
forms of MS [Costello 2014 ]and have been demonstrated to delay disease progression, prevent 
disability  and improve quality  of life.
The most commonly  used first -line MS therapi[INVESTIGATOR_254094] (IFNs) and glatiramer acetate 
[Waldman 2011 ]. Relative to placebo, IFNs have been shown to reduce relapse rate b y 
approximately  27% to 36% [Calabresi 2014 ; Jacobs 1996; PRISMS Study  Group 1998; The 
IFNB Multiple Sclerosis Study Group 1993] , and glatiramer acetate by [CONTACT_3450]  30% 
[Johnson 1995 ]. The IFN beta-1a products have also been shown to delay  disability  progression 
[Jacobs 1996; PRISMS Study  Group 1998] .
Other currentl y approved therapi[INVESTIGATOR_254095]:
Natalizumab: a humanized monoclonal antibody  directed against α4 integrins 
[Polman 2006 ]
Fingolimod: a selective oral immunosuppressant that is metabolized to a functional 
antagonist of sphingosine 1- phosphate receptors on ly mphocy tes [Kappos 2010]
Mitoxantrone: a synthetic antineoplastic anthracenedione that intercalates into 
deox yribonucleic acid and interferes with ribonucleic acid [Chitnis 2012 ]
Teriflunomide: an immunomodulatory  drug inhibiting py rimidine synthesis by  
[CONTACT_254103] e dehy drogenase [O'Connor 2011]
Alemtuzumab: a humanized monoclonal antibody targeting CD -[ADDRESS_309029] leukocy tes[Coles 2012]
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and To lerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
233.2.3. Profile of Previous Experience With ALKS 8700
[IP_ADDRESS]. Clinical Studies
Five Phase I studies to evaluate the safet y, tolerability , and pharmacokinetics (PK) of 
ALKS 8700 in healthy  adults (AL K8700 -001, ALK8700 -A102, ALK8700 -A103 and 
ALK8700 -A104, ALK8700
-A105) have been completed. Three Phase 1 studies (ALK8700-106, 
ALK8700 -107, and ALK8700 -A109) have been clinically  completed and the data anal yses are 
ongoing.
The ge neral PK 
characteristics for ALKS [ADDRESS_309030] been evaluated in the abovementioned 
completed Phase 1 studies. AL KS 8700 undergoes rapid pres ystemic h ydrolysis to MMF with a 
dose proportionate increase in MMF exposure over the ALKS 8700 dose range tested (49 to 
980mg; ALK8700 -001). Administration of AL KS 8700 420 mg with a high -fat, high -calorie 
meal delay ed absorption of MMF, resulting in a significant decrease in C max(44%) and a modest 
reduction in area under the plasma concentration versus time curve calc ulated using the 
trapezoidal method from time zero to the last observed concentration above the lower limit of 
quantification (AUC last11%, ALK8700- A102). Minimal accumulation of MMF was observed in 
plasma following repeated administration of 210 to 630 mg BID for 5days (ALK8700- A102). In 
addition, RDC -6567 has been identified as a major human metabolite of ALKS 8700 that is 
primarily  eliminated in urine (ALK8700- A105).
The relative bioavailability  of ALKS 8700 462 mg compared with DMF 240 mg was initially
evaluated in a fasted condition (AL K8700 -A103) as well as in the presence of a high -fat, 
high-calorie meal (ALK8700-A104). ALKS 8700 462 mg resulted in similar MMF exposure to 
DMF 240 mg under fasted conditions and met the PK criteria for bioequivalence t o DMF based 
on C maxand AUC (ALK8700- A103). ALKS 8700 462 mg resulted insimilar MMF exposure to 
DMF 240 mg with a high- fat, high -calorie meal and met the PK criteria for bioequivalence to 
DMF for AUC, but C maxwas 26% lower for ALKS 8700 as compared to DM F 
(ALK8700 -A104).
Given the reduction in C maxwith a high- fat, high -calorie meal, an additional study  was conducted 
evaluating meal compositions with lower fat and caloric content. In this study  (ALK8700- A109), 
MMF AUC for ALKS 8700 when administered with medium -fat, medium -calorie and low -fat, 
low-calorie meals was comparable to DMF under fasted conditions. Administration of 
ALKS 8700 with medium -fat, medium -calorie and low -fat, low -calorie meals resulted in 
reductions in C max that were less than that obse rved for DMF when administered with a high- fat, 
high-calorie meal (ALK8700- A109). Therefore, when co- administered with medium -fat, 
medium -calorie and low -fat, low -calorie meals, ALKS [ADDRESS_309031] 
demons trated that ALKS 8700 has been generally  well tolerated at all doses tested 
(49mg-
980 mg) with no reported serious adverse events (SAEs) and no unanticipated or 
Protocol ALK8700 -A301, Version 5.[ADDRESS_309032] s. All repor ted 
treatment -emergent adverse events ( TEAEs) have been mild or moderate in severit y 
(predominantl y mild), and there have been no relevant differences in tolerability  between single 
and repeat dosing at the same dose levels. The most commonly  reported TEAE s have been 
flushing followed b y gastrointestinal ( GI)-related TEAEs which have both occurred in a 
dose-dependent manner. GI -related TEAEs have been observed with ALKS 8700 at consistently  
low rates throughout the studies at dose levels comparable (in term s of MMF exposure) to the 
therapeutic maintenance dose of DMF (240 mg). Results from Phase 1 clinical investigations 
available to date on the PK, safet y, and tolerability of ALKS 8700 are summarized in the 
Investigator’s Brochure.
[IP_ADDRESS]. Nonclinical Studies
A com prehensive series of nonclinical studies were conducted to support the clinical 
development of ALKS 8700 and are described in more detail in the ALKS 8700 Investigator ’s 
Brochure.
Results from genetic toxicity  assay s showed that ALKS 8700 was non- mutagenic in bacteria 
invitro and was associated with chromosomal aberrations in vitro in human peripheral blood 
lymphocy tes but not in vivo in rats. ALKS 8700 had limited capacit y to inhibit human ether -
à-
go-go-related gene (hERG ) potassium channel activity  in a human cell line (i .e.,concentration 
resulting in 50% inhibition of response [IC50]> 300 µM). I nhibition of hERG current has been 
associated with increased duration of the cardiac action potential and prolongation of the QT 
interval.
General toxicology  findings were generally  similar to those described for DMF and consisted of 
target organ effects in kidney (tubular degeneration/necrosis with regeneration, tubular 
hypertrophy , and interstitial fibrosis in rats, mice, and/or monkey s), GI tract (mucosal 
hyperplasia of the nonglandular stomach and duodenum of rats and/or mice), bone (phy seal 
dysplasia of proximal and distal femur and proximal tibia in monkey s), heart 
(inflammation/necrosis in rats), and testes (minimal degeneration in mice).
ALKS 8700 was eval uated for developmental and reproductive toxicity  in rats and rabbits. In 
fertility  studies in male and female rats, no notable fertility  or embry onic developmental findings 
occurred. In embry o-fetal development studies in rats and rabbits, noteworthy  findings of fetal 
vertebral malformations were observed in rabbits but not in rats.
The safet y evaluation of ALKS 8700 and its metabolites (i.e., MMF, RDC -6567, and RDC -8439) 
was adequate as s ystemic exposures of these analytes in nonclinical studies were simi lar to or 
exceeded those in humans at the Phase 3 clinical dose of 924 mg/day  (462 mg BID) of 
ALKS 8700. For the major human metabolites, MMF and RDC -
6567, the exposures associated 
with adverse findings in nonclinical safet y studies are detailed in the ALK S 8700 Investigator ’s 
Brochure.
Data generated through additional nonclinical studies will continue to be evaluated as they  
become available, including an y potential influence on the risk -benefit profile of ALKS 8700.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and To lerability of ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
25See the Investigator’s Brochure for further detailed information on relevant nonclinical and 
clinical studies
3.3. Benefit-Risk Assessment
The potential risks related to participation in this study  are justified by  [CONTACT_254104] s.
Detailed information about the known and expect ed benefits and risks and reasonabl y expected 
adverse events (AEs) of ALKS 800 is provided in the Investigator ’s Brochure and informed 
consent form (I CF).A high-level summary  of those benefits and risks known during stud y 
design is provided here.
ALKS [ADDRESS_309033], DMF. An oral 
form of DMF has been approved b y the US Food and Drug Administration since 2013 under the 
trade name [CONTACT_254126]®for the treatment of patients with relapsing forms of MS [Tecfidera®
Prescribing Information 2017/SmPC 2017 ].
In clinical trials, DMF and, by  [CONTACT_5259], its metabolite, MMF, have demonstrated robust 
efficacy  in modulating the course of diseas e in patients with RRMS. Compared with placebo, 
DMF treatment resulted in significant reductions in annualized relapse rate (ARR), disability  
progression, as well as the number of new gadolinium- enhancing (GdE) lesions and new or 
enlarging T2 lesions [Fox 2012; Gold 2012; Kappos 2008 ].
The safet y profile of DMF is 
well understood and GI -related tolerability  is a recognized 
tolerability  concern. As noted in the Summary  Review of the Drug Approval Package for 
Tecfidera, in placebo -controlled trials of Tecfidera, 40% of DMF -treated subject s experienced 
one or more GI A Es. Reviewers described “a panoply  of uncomfortable and fairl y common GI 
AEs” that are an “obstacle to tolerability ,” including nausea, vomiting, diarrhea, and abdominal 
pain [FDA 2013 ]. In addition, GI  AEs were the leading cause of discontinuations due to AEs 
[FDA 2013 ]. The frequency  and severity  of the GI -related side effects are an important issue for 
patients taking DMF and is a barrier to treatment adherence and can lead to drug discontinuation 
which increases risk of relapse [Phillips 2014; Utz 2014] . This underscores the need for an 
efficacious agent with improved tolerabilit y to optimize patient satisfaction and treatment 
outcomes [Phillips and Fox 2013 ].
The ALKS [ADDRESS_309034] s:
De Novo Subject s:Those who have not participated in any  prior eligible study  of ALKS 8700.
Rollover Subject s:Those who have completed the treatment period for an y prior eligible stud y of 
ALKS 8700.
For De Novo Subject s, the study  duration is expected to be up to [ADDRESS_309035] s will be initially  evaluated for eligibility  at screening (Visit 1) that may  last up 
to 28 day s (4 weeks) prior to Visit 2. For Rollover Subject s, Visit [ADDRESS_309036] ’s end of treatment visit in the antecedent 
study . Completed assessments taken at the end of treatment visit of the antecedent study  will be 
carried forward and do not need to be repeated at Visit [ADDRESS_309037] dose of ALKS 8700 at Visit 2 (Day  1). From that point on 
during the treatment period, according to the schedule of assessmen ts as shown in Table 1, the 
staff will dispense ALKS [ADDRESS_309038] s’ self -administration. Subject s will be instructed to 
take study  treatment with or without food. However, 
subject s will be instructed to avoid taking 
study  treatment with a high- fat, hig h-calorie meal.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
28During the 96 -week treatment period (Visits 2- 15), subject s will return to the clinic for periodic 
scheduled visits for the assessment of safet y, tolerability , PK (in a subset of de novo subject s in 
selected sites), and clinical status. Two safet y and tolerability assessments by [CONTACT_254105] (one between Visits 2 and 3 and one between Visits 3 and 4). See Figure 1for a study  
schematic .
Subject s will return to the clinic for a safety  follow -up visit (Visit 16) 2 weeks after the en d of 
treatment visit (Visit 15). Any  subject who prematurely  discontinues from either study  treatment 
or the study will be asked to return to the clinic for an earl y termination (ET) visit (Visit 15) as 
well as a safet y follow- up visit 2 weeks later (Visit 16).
Subject s who complete the study  or who terminate the study  early and have a last measured 
lymphocy te count < 0.8 × 103/µL will return to the clinic for additional lymphocy te count 
monitoring visits every  2 months starting from Visit 16 for a period o f 6 months (i .e., a 
maximum of 3 visits) or until ly mphocy te counts reach normal limits ( ≥0.91 × 103/µL), 
whichever occurs first .
A treatment completer will be a subject who completes the 96 -week treatment period (i.e., 
through Visit 15). Subject s completi ng the follow -up visit will be categorized as completing the 
study .
The end of stud y date for a 
subject may be the last study  visit, last follow -up telephone 
conversation, or last protocol-specified assessment, or if the subject has ongoing AEs that are 
being followed, the date may  be the date of AE resolution.
5.3. Study treatment Dose Adjustment and Stoppi[INVESTIGATOR_254096]  8 of treatment, dose reduction to ALKS 8700 231 mg BID is permitted at the 
Investigator ’s discretion for subject s who are unable to tolerate ALKS [ADDRESS_309039] remains unable to 
tolerate ALKS 8700 462 mg BIDafter 1 month on treatment (i.e., by  [CONTACT_4838] 4), further dose 
reduction will not be permitted, and the subject will be discontinued from the study .
The Sponsor may terminate this study  at an y time, after informing Investigator s. The Sponsor 
will notify  Investigat ors when the study  is to be placed on hold, completed, or terminated.
5.4. Unscheduled Visits
Data collected during unscheduled visits should be recorded in electronic case report forms 
(
eCRFs) onl y if the data support protocol objectives and/or are required f or safet y monitoring.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
29An Unscheduled Relapse Visit will be conducted in the event of a suspected relapse
(Section 7.2.2). This visit should occur as earl y as possible but within 7 days of the onset of the 
potential relapse. The following assessments will b e made:
Physical examination
Concomitant medication review
AE monitoring
Urine pregnancy  test
Vital signs
Safety  laboratory  assessments
Relapse assessment
EDSS
5.5. Follow -
up
Subject s will return to the clinic for a safety  follow -up visit (Visit 16) 2 weeks aft er the end of 
treatment visit (Visit 15) for the required assessments ( Table 1). An y subject who prematurel y 
discontinues from the study  will be asked to return to the clinic for an ET visit (Visit 15) as well 
as a safety  follow -
up visit 2 weeks later (Vis it 16) for the required assessments ( Table 1).
Subject s who complete the study  or who terminate the study  early and have a last measured 
lymphocy te count < 0.8 × 103/µL at the last study visit (Visit 16) will be required to return to the 
clinic for additio nal ly mphocy te count monitoring visits every  2 months (± 7 day s) starting from 
the last study  visit for a period of 6 months (i
.e., a maximum of 3 vi sits) or until ly mphocy te 
counts reach normal limits ( ≥0.91 × 103/µL), whichever occurs first ( Table 2).
During the ly mphocy te count monitoring visits, blood samples will be collected to measure 
lymphocy te count and any  concomitant medications the subject s are taking will be recorded 
(Section 7.7).
5.6. End of Study
The end of stud y is last subject , last visit for final collection of data.
Protocol ALK8700 -A301, Version 5.[ADDRESS_309040] meet all of the 
following criteria:
1.Is willing and able to provide informed consent.
2.Capable of understanding and complying with the protocol .
3.Agrees to use an acceptable method of contraception for the duration of the study  and for 
30 day s after any  study  treatment administration or is surgically  steril e or postmenopausal 
(see Section 11.5).
4.Completed the full treatment period of an y eligible study  of ALKS [ADDRESS_309041] meet all of the 
following c riteria:
1.Is willing and able to provide informed consent .
2.Capable of understanding and complying with the protocol .
3.Agrees to use an acceptable method of contraception for the duration of the study  and for 
30 day s after any  study  treatment administration o r is surgically  sterile or postmenopausal 
(see Section 11.5).
4.Male and female adults aged 18 to 65 years, inclusive, at screening .
5.Has a confirmed diagnosis of RRMS according to the revised 2010 McDonald criteria 
[Polman 2011 ].
6.EDSS 
score of 0.[ADDRESS_309042] swill be exclu ded from participation in this trial if they  meet any  of the 
following criteria:
1.Have an y finding(s) that in the view of the Investigator or Medical Monitor would 
compromise the safety  of the subject , affect their ability  to adhere to the protocol visit 
schedule, or to fulfill visit requirements or make the subject unsuitable for participation in 
the study  (including overall clinical assessment) .
2.Subject is pregnant or breastfeeding or plans to become pregnant or begin breastfeeding 
at an y point during the 
study  and for [ADDRESS_309043] research organization (CRO) ,or study  site (permanent, 
temporary  contract worker, or designee responsible for the conduct of the study ) or is 
immediate family  of a Biogen , CRO, or study  site employ ee. Immediate family  is defined 
as a spouse, parent, sibling
, or child, whether biological or legall y adopted .
6.2.2. De Novo Subject s
De Novo Subject swill be excluded from participation in this trial if they  meet any  of the 
following criteria:
1.Have an y finding that in the view of the Investigator or the Medical Monitor would 
compromise the safety  of the subject or affect their ability  to adhere to the protocol visit 
schedule or fulfill visit requirements or make the subject unsuitable for participation in 
the study  (including overall clinical assessment) .
2.Diagnosis of primary  progressive, secondary  progressive, or progressive relapsing MS as 
defined b y Lublin and Reingold [Lublin and Reingold 1996
].
3.History  of clinically  significant cardiovascular, pulmonary , GI (e. g., inflammatory  bowel 
disease, peptic ulcer disease), dermatologic, ps ychiatric, neurologic (other than MS), 
endocrine, renal and/or other major disease that 
would preclude participation in a clinical 
trial.
4.History  of clinically  significant recurring or active GI symptoms (e . g., nausea, diarrhea, 
dyspepsia, constipation) within 3 months of screening, including sy mptoms that require 
the initiation of sy mptomati c medical treatment (e .g., initiation of a medication to treat 
gastroesophageal reflux disease) or a change in symptomatic medical treatment (e .
g., an 
increase in dose) within 3 months of screening .
5.History  of malignancy , unless an exception is granted by  [CONTACT_1689] 
(e.g.,subject swith basal cell carcinoma that has been completel y excised prior to study  
entry  remain eligible) .
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
326.Has a clinicall y significant medical condition or observed abnormality at screening 
(e.g.,clinicall y significant physical examination finding, vital sign result, ECG result, or 
laboratory  test result) .
7.History  of a m yocardial infarction, including a silent myocardial infarction identified on 
ECG, or unstable angina .
8.History  of clinically  significant drug or alcohol abuse wit hin the past y ear 
(perInvestigator judgment) .
9.Has a positive serology  test for hepatitis B surfa ce antigen, hep atitis C antibody , or 
human immunodeficiency virus (HIV) antibody  at screening .
10.Has an y of the following abnormal blood tests at screening:
Alan ine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2 times the 
upper limit of normal (ULN)
Thyroid
-stimulating hormone (TSH) level >10% of the ULN at screening
Estimated glomerular filtration rate (eGFR) ≤60 mL /min/1.73 m2(using the Chronic 
Kidney Disease Epi[INVESTIGATOR_254097] )[Leve y 2009 ]
Lym phocy te count < 0.9 × 103/μL
11.Has an y of the following abnormal urine tests at screening:
Beta-2 microglobulin > 0.3 μg/mL
Albumin to creatinine ratio > 200 mg/g
12.Has a clinicall y significant history of suicidal ideation or suicidal behavior occurring in 
the past 12 months as assessed b y the C -SSRS at screening.
13.Has previousl y discontinued treatment with Tecfidera due to tolerability issues and/or 
lack of efficacy .
14.Has a history  of treatment with or has received the following:
Total ly mphoid irradiation, cladribine, T- cell or T -cell receptor vaccination, total 
body  irradiation ,or total ly mphoid irradiation at any  time
Stem cell transplantation at an y time
Mitoxantrone or other immunosuppressant agents (e.g., cy closporine, 
cyclophosphamide, methotrexate, my
cophenolate) within 2 y ears prior to Visit 2
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
33Teriflunomide within 2 years of Visit 2, unless the serum/plasma concentration of 
teriflunomide is < 0.020 μ g/mL  (<20ng/mL) prior to Visit 2 (an accelerated 
elimination procedure for teriflunomide with cholesty ramine is permitted dur ing 
screening)
Natalizumab within 2 months prior to Visit 2 or any prior use of alemtuzumab
Fingolimod within 90 day s prior to Visit 2
Daclizumab within 6 months prior to Visit 2
B
-cell targeted therapi[INVESTIGATOR_25663] (e .g., ocrelizumab, rituxim ab) within 
12 months of screening; greater than [ADDRESS_309044] returned to within normal range (per local 
lab
oratory reference range)
Eligibility  related to prior treatment with an investigation al drug and/or a 
commerciall y available drug for the treatment of MS not listed above within the past 
24 months will be determined on a case -by-case basis by  [CONTACT_1689]
Steroids, with the exception of topi[INVESTIGATOR_180123], or intravenous ( IV)
immunoglobulin within [ADDRESS_309045] is pregnant or breastfeeding or plans to become pregnant or begin breastfeeding 
at an y point during the study and for 30 day s after any  study  treatment administration .
17.Is employ ed by  [CONTACT_204903] , CRO ,or study  site (permanent, temporary  contract worker, or 
designee responsible for the conduct of the stud y) or is immediate family  of a Biogen , 
CRO, or study  site employ ee. Immed iate family  is defined as a spouse, parent, sibling ,or 
child, whether biological or legally  adopted .
6.3. Screen ing, Retesting, and Screen Failures
6.3.1. Screening
Once informed consent is obtained, screening assessments can occur. At this time, a unique 
identificat ion number is assigned that will be used on study -related documents pertaining to the 
subject . Any identification numbers that are assigned will not be reused even if the subject
does 
not receive tre atment or continue in the study . Study sites are required to document all screened 
subject s initially  considered for inclusion in the study .
6.3.2. Retesting
Not applicable .
Protocol ALK8700 -A301, Version 5.[ADDRESS_309046] dose of 
ALKS 8700 at Visit 2 (Day  1). From tha t point on during the treatment period, the staff will 
dispense ALKS [ADDRESS_309047] s’ self -administration. Subject s will be instructed to take study  
treatment with or without food. However, subject s will be instructed to avoid taking study  
treatment with a high
-fat, high -calorie meal. Detailed dosing instructions will be provided to the 
patients by  [CONTACT_14523].
7.2. Modification of Dose and/or Treatment Schedule
Starting on Day  8 of treatment, dose reduction to ALKS 8700 231 mg BID is permitted at the 
Investigator ’s discretion for subject s who are unable to tolerate ALKS [ADDRESS_309048] has stabilized after dose reduction, attempts should again be made to achieve and 
maintain the target maintenance dose of ALKS 8700 462 mg BID. If a subje ctremains unable to 
tolerate ALKS 8700 462 mg BIDafter 1 month on treatment (i .e., by  [CONTACT_4838] 4), further dose 
reduction will not be permitted, and the subject will be discontinued from the study .
In the event of a suspected relapse (new s ymptoms or worsen
ing s ymptoms), subject s will be 
asked to call the treating neurologist within 48 to 72 hours of the onset of the symptoms to 
determine the necessit y of an Unscheduled Relapse Visit . An Unscheduled Relapse Visit will be 
conducted as described in Section 5.4. Further instruction is also provided in Section 7.2.2.
Should progressive multifocal leukoencephalopathy  (PML) be suspected by  [CONTACT_254106] s ymptoms or signs during the relapse visit, study  treatment will be withheld 
and an appropria te diagnostic work
-up should be performed as soon as possible (within 14 days 
of the relapse visit). If PML  is excluded based on the diagnostic work- up, the subject may 
resume taking study  treatment if approved b y the Medical Monitor. If the diagnostic wor k-up 
exceeds [ADDRESS_309049] also be temporaril y withheld if any of the following laboratory  parameters 
meet the following threshold limits:
AST or ALT > 3 ×ULN; confirmed b y repeat testing as soon as possible. If the value 
remai ns > 3 ×ULN for ≥ [ADDRESS_309050] permanently  discontinue study  treatment.
Lym phocy te count < 0.5 × 109/L; confirmed b y repeat testing as soon as possible. I f 
the value remains < 0.5 × 109/L for ≥ [ADDRESS_309051] permanentl y discontinue study treatment. ( Subjects who 
permanentl y discontinue the study with a last measured lymphocy te count 
< 0.8 × 103/µL will require additional follow -up to monitor their ly mphocy te counts .)
eGFR < 60 mL/min/1.73 m2; confirmed by  [CONTACT_254107]. If the 
eGFR remains < 60 mL/min/1.73 m2for ≥
4weeks after discontinuation of study  
treatment, the subject must permanentl y discontinue study treatment.
Urine albumin to urine creatinine ratio > 200mg/g; confirmed by  [CONTACT_254108]. If the urine albumin to urine creatinine ratio remains > 200mg/g for 
≥ 4weeks after discontinuation of study  treatment, the subject must permanently  
discontinue st udy treatment.
Resuming study  treatment after it has been withheld is to be considered on a case b y case basis 
and must be discussed with the Medical Monitor.
The study  may  be stopped at any  time or study  sites may  be closed at the Sponsor’s discretion.
7.2.1. Rescue
Subject s will be eligible to remain on assigned study  treatment for 96 weeks, even if they  
experience a relapse (see Section 7.2.2). In the event of a confirmed acute event (relapse), the 
treating neurologist may  opt to prescribe 1000 mg of oral or IVmethy lprednisolone treatment 
(administered once dail y or in divided doses) for [ADDRESS_309052] ’s eligibility  to continue in the study . The 
subject will continue on study  treatment while being treated with methy lprednisolone. 
Subject s 
may also refuse relapse treatment. Any  deviations from this recommended treatment must first 
be discussed with the Medical Monitor.
7.2.2. Relapse
Efficacy  anal yses related to MS relapse include only  events of protocol -defined relapse. 
Protocol -defined relapse consists of the following:
New or recurrent neurologic s ymptoms, not associated with fever or infection, lasting 
for at least 24 hours, accompanied by  [CONTACT_10980]:
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
37New objective neu rological findings upon examination by  [CONTACT_254109] (performed within 
7days of onset of s ymptom s) with an increase over the prior visit of ≥0.5 for the 
total score,
An increase of ≥ 2 in 1 functional sy stem (FS), except bladder/cognitive changes, 
and/or,
An increase of 
≥1 in 2 FS, except bladder/cognitive changes.
New or recurrent neurologic s ympt
oms that evolve graduall y over months should be considered 
disability  progression, not an acute relapse, and should not be treated with corticosteroids. New 
or recurrent neurologic sy mptoms that occur less than 30 day s following the onset of a protocol 
defined relapse should be considered part of the same relapse and would not be treated with oral 
or IV methy lprednisolone within the protocol.
Subject s who experience new neurologic s ymptoms must contact [CONTACT_254110] 48 -72 hours of the onset of s ymptoms to determine the necessit y of 
an Unscheduled Relapse Visit (see Section 5.4).
If required, the 
subject will then be evaluated in person by  [CONTACT_254111] 7 days of the onset of the potential relapse.
The neurologist is to perform a relapse assessment and obtain an EDSS score. New 
objective findings on neurological examination performed b y the neurologist in 
conjunction with the EDSS changes described above will confirm whether the 
suspected protocol -defined relapse has occurred.
Treatment of the acute event may  then proceed at the discretion of the neurologist
(according to the meth ylprednisolone regimen described in 
Section 7.2.1) only after 
the 
neurologist has completed his/her examination. Treatment of an acute event of 
relapse with oral or IV methy lprednisolone will not affect the subject ’s eligibility  to 
continue in the study .
Subject s must provide written confirmation of their willingness to continue 
participation in the study  upon any  determined e vent of MS relapse as described in
Section 13.5.
7.3. Study Treatment Management
Study  treatment will be manufactured, handled, and stored in accordance with applicable Good 
Manufacturing Practice (GMP) .
Study  treatment must be dispensed only  by a pharmacist o r appropriatel y qualified staff. Stud y 
treatment is to be dispensed only  to subject s enrolled in this study . Once study  treatment is 
Protocol ALK8700 -A301, Version 5.[ADDRESS_309053] . Study  treatment is for one -time 
use only ; do not use a ny study  treatment remaining in the vial for another subject .
7.3.1. ALKS [ADDRESS_309054] minitablets contained 
within a hy droxypropyl methy lcellulose capsule for oral administration.
The doses of ALKS 8700 D R to be used in this study  are 231 mg (administered as one capsule) 
and 462 mg (administered as two 231 mg capsules). Capsules will be administered orall y,BID.
[IP_ADDRESS]. P ackaging and Labeling
ALKS 8700 DR capsules are supplied in both 20- count, 100 cc, induction s ealed, high densit y 
polyethylene ( HDPE) bottle and 64 count, 150 cc, induction sealed, HDPE bottle configuration.
Labeling will meet all applicable local and regulatory  requirements.
[IP_ADDRESS]. Storage
All study  materials are to be stored at room temperature not to exceed 25°C in a secure location.
[IP_ADDRESS]. Handling and Disposal
Following completion and verification of accountability  logs, all unused and used packages must 
be destroyed. Packages may be destro yed on site according to Good Clinical Practice (GCP) and 
site pract ice. Alternatively , the Sponsor may  arrange for destruction with a third party  vendor 
operating in accordance with GCP and/or GMP, as applicable.
[IP_ADDRESS]. Accountability
Accountability  for study  treatment is the responsibility  of the Investigator . The study  site must 
maintain accurate records demonstrating dates and amount of study  treatment received, to whom 
dispensed, amount returned by  [CONTACT_423] , and accounts of any  study  treatment accidentall y or 
deliberatel y destro yed or lost. 
Unless otherwise notified, all packaging both used and unused, must be saved for study  treatment 
accountability . By [CONTACT_2054] , reconciliation must be made between the amount of
ALKS [ADDRESS_309055] be provided for an y discrepancies.
7.4. Blinding Procedures
Not applicable. The study is open -label.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
397.5. Precautions
In the event of a confirmed acute event (relapse), the treating neurologist may  opt to prescribe 
1000 mg of oral or IV methy lprednisolone treatment (administered once daily  or in divided 
doses) for [ADDRESS_309056] ’s eligibility  to continue in the study . The subject will continue on study  treatment 
while being treated with methy lprednisolone. Subject s may  also refuse relapse treatment. Any  
deviations from this recommended treatment must first be discussed with the Medical Monitor.
7.6. Compliance
Compliance with treatment dosing is to be monitored and rec orded by  [CONTACT_6624].
According to the schedule in Table 1, at each specified dispensing visit, subject s will receive a 
supply  of ALKS [ADDRESS_309057] s will be instructed to bring an y 
unused drug and the bottle(s) with them t o each subsequent visit. Drug adherence will be 
reviewed with subject s at each visit.
7.7. Concomitant Therapy and Procedures
7.7.1. Concomitant Therapy
A concomitant therap y is any drug or substance administered between the time the subject is 
enrolled in the study  
and until the completion of the safet y follow -up visit (Visit 16).
Subjects should be instructed to contact [CONTACT_58401] s before taking any  new medications, 
including nonprescription drugs and herbal preparations.
[IP_ADDRESS]. Allowed Concomitant Therapy
At scree ning all De Novo Subjects will be asked about the medications they have taken in the 
last [ADDRESS_309058] to qualify  for the study , those exclusions outlined in 
Section [IP_ADDRESS] must be ruled out. At each subsequent study  visit, review of c oncomitant 
medications will be repeated for all subject s. Concomitant medications to be reviewed at each 
study  visit include prescription and nonprescription medications, vitamins, and supplements.
The Investigator will record the following data on all med ications used b y the subject s: name, 
dose, regimen, route of administration, start and stop dates, and the indication for use.
[IP_ADDRESS]. Disallowed Concomitant Therapy
Immunomodulatory  treatments for RRMS (besides study  treatment ) are prohibited during 
treatment wit h study  treatment unless approved by [CONTACT_1689]. Prohibited 
immunomodulatory  therapi[INVESTIGATOR_31430], but are not restricted to the following:
Any alternative drug treatments directed toward the treatment of MS such as chronic 
immunosuppressant therapy
 or other immunomodulatory  treatments (including, but 
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
40not limited to: IFN-beta, IFN-alpha, glatiramer acetate, DMF, natalizumab, 
cyclophosphamide, methotrexate, azathioprine, teriflunomide, and fingolimod)
Of note, the timing of discontinuing IFN-beta, IFN-alpha, glatiramer acetate ,or 
DMF prior to initiating treatment with study  treatment (Visit 2) is at the 
Investigator ’s discretion
The initiation of a DMT for the treatment of RRMS is permitted if initiated after 
the last dose of study  treatment (it is also preferable that it be initiated at least 1 
day after Visit 15 and not on Visit 15)
Any investigational product, including investigational sy mptomatic therapi[INVESTIGATOR_254098] -MS indications
Total ly mphoid irradiation, cladri bine, T -cell or T -cell receptor vaccination, any  
therapeutic monoclonal antibody , mitoxantrone, cy closporine, IV immunoglobulin, 
plasmapheresis, or cy tapheresis
The use of corticosteroids for the treatment of clinical relapses and steroids that are adminis tered 
by [CONTACT_254112] (e .g., inhaled or topi[INVESTIGATOR_2855]) are permitted. 
Symptomatic therapy , such as treatment for spasticity , depression, or fatigue is not prohibited but 
should be optimized as early as possible after screening in an attempt to maintain co nsistent 
treatment during the study .
Immunization using inactivated, killed, or viral particle vaccines (e .g., influenza vaccine) is 
permitted and can be administered according to Investigator judgment. Vaccines using live or 
attenuated viruses should not be administered unless approved b y the Medical Monitor.
Subject s should be instructed not to start taking any  new medications, including nonprescribed 
drugs, unless they  have received permission from the Investigator .
See Section [IP_ADDRESS] for details regard
ing the concomitant medication review .
7.7.2. Concomitant Procedures
A concomitant procedure is any  therapeutic intervention (e.g., surgery /biopsy , phy sical therap y) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
the time the subject is enrolled in the study  and until the completion of the safet y follow- up visit 
(Visit 16) .
7.8. Continuation of Treatment
No further provisions are made for access to the study  treatment following trial completion.
Protocol ALK8700 -A301, Version 5.[ADDRESS_309059] permanently  discontinue ALKS 8700 for an y of the following reasons:
The subject becomes pregnant. Stud y treatment must be discontinued immediatel y. 
Report the pregnancy  according to the instructions in Section 11.4.1 .
The subject withdraws consent to continue study  treatment. 
The subject experiences an AE that necessitates permanent discontinuation of study  
treatment.
At the discretion of the Investigator formedical reasons.
The primary  reason for discontinuation of study  treatment must be recorded in the subject ’s 
eCRF.
Any subject who prematurely  discontinues from either study  treatment or the study  will be asked 
to return to the clinic for an ET visit (Vis it 15) as well as a safet y follow
-up visit 2 weeks later 
(Visit 16) for the required assessments. Please see Section 5.5for the follow -up of subject s with 
lymphopenia.
8.2. Lost to Follow -Up
Subject s will be considered lost to follow -up if they repeatedly  failto return for scheduled visits 
and are unable to be contact[INVESTIGATOR_530] b y the stud y site. 
The following actions must be taken if a subject fails to return to the study  site for a required 
study  visit:
The site must attempt to contact [CONTACT_254113] e missed visit as soon as 
possible and counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether the subject wishes to and/or should continue in the study .
In cases in which the subject is deemed lost to follow -up, the Investigator or designee 
must make every  effort to regain contact [CONTACT_1155] . These contact [CONTACT_254114] ’s medical record.
Should the subject continue to be unreachable, that subject will be considered to have 
withdrawn from the study with a primary  reason of lost to follow -up.
Protocol ALK8700 -A301, Version 5.[ADDRESS_309060] who completes the 96 -week treatment period (i .e., 
through Visit 15). Subject s completing the follow -up visit 
will be categorized as completing the 
study .
A subject may be withdrawn from the stud y at any time if the subject , Investigator , or Sponsor 
determines that it is not in the best interest of the subject to continue participation. Reasons for 
discontinuation include:
AE
Lack of efficacy
Lost to follow -up
Withdrawal by  [CONTACT_1130]
Protocol deviation (noncompliance with study  treatment or study procedures)
Physician decision
Pregnancy
Study  terminated by  [CONTACT_2728]
Other
If a subject withdraws from the study  for any  reason , any  ongoing AEs will be followed until 
resolution, until deemed stable by  [CONTACT_737] , or until the subject is deemed b y the 
Investigator to be lost to follow -up. If, in the opi[INVESTIGATOR_689] , it is necessary  to 
monitor a subject beyond the safet y follow -up visit, the follow -up period may  be extended as 
necessary . In such instances, the Sponsor and the Investigator will agree to an acceptable 
follow -up schedule. If a subject withdraws from the study  and has a last l ymphocyte count whic h 
is <0.8 × 103/µL, the subject will return to the clinic for additional l ymphocy te count monitoring 
visits every  2 months starting from the safet y follow -up for up to 6 months (i.e., a maximum of 
3visits) or until the ly mphocy te count reaches normal lim its (≥0.91 × 103/µL), whichever occurs 
first.
In the event that a subject chooses to withdraw from the study , the Investigator should make a 
reasonable effort to ascertain the reason(s) for withdrawal, while fully  respecting the subject ’s 
rights. Subject s discontinuing 
study  treatment and withdrawing from the study  are to be asked to 
return to the clinic for an ET visit. The ET visit should be scheduled as close as possible to the 
subject ’s last dose and will mimic the assessments scheduled to be conducted at Visit 15.
Following the ET visit, subject s will be asked to participate in the safet y follow -up period. If the 
subject fails or refuses to return to the study  site, an attempt must be made to contact [CONTACT_254115]8700 -A301, Version 5.[ADDRESS_309061] ’s record.
The Investigator must maintain a record of all subject s who fail to complete the study . The 
reason for study  discontinuati on will be documented and made on the app ropriate eCRF. If a 
subject is lost to follow -up, a reasonable attempt to contact [CONTACT_423] s must be made and 
documented.
Subject s who withdraw from the study after receiving the first dose of study  treatment may not
be replaced.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
[IP_ADDRESS]. EuroQol Group Health O utcome Measure (5 level; EQ -5D- 5L)
The EQ -5D- 5L™is a trademark of the EuroQol Group©and is an instrument designed to assess 
decrements in health. The EQ-5D- 5L includes a Visual Analog Scale (VAS) and a descriptive 
system that defin es health in terms of 5 dimensions: Mobility , Self -Care, Usual Activities, 
Pain/Discomfort, and Anxiety /Depression. Each dimension has 5 response categories 
corresponding to the level of severit y (i.e., no problems, slight problems, moderate problems, 
severe problems
, and unable to/extreme problems). Subjects will complete the questionnaire 
according to the schedule in Table 1. A sample of the EQ-5D- 5L will be provided to study  sites 
outside of this protocol.
9.1.3. Timed 25 -Foot Walk
The T25
-FW [ Kaufman 2000] is a reliable quantitative mobility  and leg function performance 
test based on a timed [ADDRESS_309062] s are allowed to 
use assistive devices (canes, crutches, walkers) as needed. The time is calculated from when the 
lead foot crosses the start point to when the subject has reached the 25-foot mark. The task is 
immediately  administered again b y having the subject walk back the same distance. The score 
for the T25- FW is the average of the 2 completed trials.
[IP_ADDRESS]. Short Form 12 Health Survey
Quality  of life will be assessed using the 12-item Short -Form health survey  Version 2 (SF -12v2)
[Maruish 2012
]. Subject s will complete the questionnaire according to the schedule in Table 1.A 
sample of the SF -12 will be provided to the study  sites outside of this protocol.
[IP_ADDRESS]. Columbia
-Suicide Severity Rating Scale
The C -SSRS is a clinician-administered instrument that assesses suicidal ideation and behavior 
[Posner 2011
]. The “Screening” version of the instrument will be administered to De Novo 
Subject s at the screening visit. The “Since Last Visit” version will be administered to all 
participating subject s at all other visits specified in Table 1. A sample of the C -SSRS will be 
provided to the study  sites outside of this protocol.
9.2. Pharmacok inetic Assessments
PK samples will be collected from a subset of de novo subject s (approximately  50) enrolled at 
selecte d sites. 
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
47The following parameters, but are not limited to, will be calculated to assess the PK of 
ALKS 8700:
Maximum observed concentration (C max)
Time to reach C max(
Tmax)
AUC last
Concentrations of analy tes considered appropriate for further evaluation ( e.g., MMF, RDC - 6567, 
and RDC -8439) will be quantified in plasma samples collected for PK evaluation. See 
Section 12.5 for further details.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
4810. SAFETY ASSESSMENTS
See Section 1.3for the timing of all safet y assessments.
Tests and evaluations affecting primary  endpoints and/or anal yses may  need to be repeated if the 
original results are lost or damaged. In these cases, subject s
will be asked to return to the study  
site to have the evaluations repeated.
10.1. Clinical Safety Assessments
The following clinical assessments will be performed to evaluate the safety profile of ALK 8700:
AEs and SAEs 
will be monitored continuously  from the time a subject signs the I CF 
until the completion of the final study  visit ( Table 1) and additional follow -up, if 
required .
Medical histor y
.
Physical examinations : A full phy sical examination and measurement of body  height 
and weight will be performed at screening. For Rollover Subject s, height will be 
carried over from information recorded in the antecedent stud y in which they 
participated. All subject s will have brief, s ymptom -directed ph ysical examinations 
and will be weighed at timepoints specified in Table 1.
Vital sign measurements (temperature, heart rate, sy stolic and diastolic blood 
pressure, and respi[INVESTIGATOR_2842]): Blood pressure, he art rate, and respi[INVESTIGATOR_254099] a seated or supi[INVESTIGATOR_21683] 
5minutes. Consistent measurements and procedures should be used for all 
assessments (Table 1)
.
12-L ead ECGs will be performed af ter the subject has rested quietl y for at least 
5minutes in the supi[INVESTIGATOR_2547]. ECGs will be conducted using calibrated equipment 
and assessed b y a qualified clinician ( Table 1).
C
-SSRS administered by [CONTACT_15370]: The “Screening” version of the instru ment will 
be administered to De Novo subject s at the Screening Visit. The “Since Last Visit” 
version will be administered to all subject s at all other visits specified in Table 1.
Concomitant therap y and procedure recording.
10.2. Laboratory Safety Assessments
Blood and urine samples for laboratory  assessments will be collected at the timepoints specified 
in Table 1. Specific hematology , biochemistry , and urinaly sis assessments to evalu ate the safet y 
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
49profile of ALKS 8700 are listed in Table 3. Samples will be col lected in accordance with the 
site’s usual procedures and anal yzed by a central laboratory .
Samples will be analy zed using Good Laboratory  Practice -validated assay s. 
Table 3: Clinical Laboratory Assessments
Hematolog y1Biochemistry Urinalysis
Hematocrit
Hemoglobin
Red blood cell count
Total and differential (absolute) 
white blood cell count
PlateletsSodium
Potassium
Chloride
Bicarbonate
Glucose
Thyroid-stimulating hor mone 
(TSH)2
Calcium
Uric Acid
Creatinine
Total protein
Blood urea nitrogen
Albumin
Total bilirubin
Alanine aminotransferase (ALT)
Aspartate aminotransferase 
(AST)
Lactic dehydrogenase (LDH)
Alkaline phosphatase
Creatine phosphokinase
Lipid profile: blood cholesterol, 
high-density lipoprotein, 
lowdensity lipoprotein, and 
triglyceridesColor
pH
Specific gravity
Ketones
Protein
Glucose
Bilirubin
Nitrite
Urobilinogen
Occult blood
Microscopic examination of 
sediment only if urinalysis 
dipstick results are abnormal
Urine albumin
Urine beta -2-microglobulin
Urine creatinine
1Additional hematology assessments will be collected for subject s requiring follow -up for lymphopenia at the time 
of study completion or early ter mination .
2To be assessed at screening only .
10.2.1. Pregnancy Testing
A urine pregnancy  test will be administered to all women regardless of childbearing potential at 
the timepoints specified in Table 1. Results must be negative for initial study  eligibility  and
continued participation.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
5010.2.2. Serology Testing
A blood sample for a serology panel testing for hepatitis B surface antigen, hepatitis C antibody , 
and HIV antibody  will be performed at screening only  (Table 1).
Protocol ALK8700 -A301, Version 5.[ADDRESS_309063] and/or his/her legall y authorized repre sentative and/or 
main caregiver must be given the names and telephone numbers of site staff for reporting SAEs, 
pregnancies, overdoses, and medical emergencies. Throughout the protoc ol, the Sponsor is 
named, but reporting may be done through a CRO.
11.1. Definitions
11.1.1. Adverse Event
An AE is an y untoward medical occurrence in a patient or clinical investigation subject (subject )
administered a pharmaceutical product and that does not necessari ly have a causal relationship 
with this treatment. An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal assessment such as an abnormal laboratory  value ), symptom, or disease temporall y 
associated with the use of a medicinal (in vestigational) product, whether or not related to the 
medicinal (investigational) product.
Determination of whether an abnormal assessment (e.g., laboratory  value ,vital sign, and ECG )
result meets the definition of an AE will be made by  [CONTACT_737]. A bnormal results are not 
considered AEs unless one or more of the following criteria are met:
Theresult meets the criteria for an SAE .
Theresult requires the subject to receive specific corrective therap y.
The result is considered by [CONTACT_254116] .
11.1.2. Serious Adverse Event
An SAE is any  untoward medical occurrence that at any  dose:
Results in death.
In the view of the Investigator , places the subject at immediate risk of death (a 
life-threatening event); however, this does not include an event that, had it occurred 
in a more severe form, might have caused death .
Requires inpatient hospi[INVESTIGATOR_1081] .
Results in persistent or significant disability /incapacity .
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
52Results in a congenital anom aly/birth defect .
Is a medicall y important event .
Amedicall y important event is an AE that, in the opi[INVESTIGATOR_689] , may  jeopardize the 
subject or may  require intervention to prevent one of the other outcomes listed in the definition 
above. (Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or convulsions occurring at home that do not require an 
inpatient hospi[INVESTIGATOR_059].)
11.1.3. Prescheduled or Elective Procedures or Routinely Scheduled Tr eatments
A prescheduled or elective procedure or a routinely  scheduled treatment will not be considered 
an SAE, even if the subject is hospi[INVESTIGATOR_057]. The study site must document all the following:
The prescheduled or elective procedure or routinely schedul ed treatment was 
scheduled (or was on a waiting list to be scheduled) prior to obtaining the subject ’s 
consent to be in the study.
The condition requiring the prescheduled or elective procedure or routinel y scheduled 
treatment was present before and did no t worsen or progress in the opi[INVESTIGATOR_204884] ’s consent to be in the study  and the time of the 
procedure or treatment.
The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the interven tion or hospi[INVESTIGATOR_063].
oIf a subject is hospi[INVESTIGATOR_204885], the hospi[INVESTIGATOR_204886] 11.1.[ADDRESS_309064] be assessed to determine the following:
If the event meets the criteria for an SAE as defined in Section 11.1.2 .
The relationship of the event to study  treatment as defined in Section 11.2.2 .
The severit y
of the event as defined in Section 11.2.3 .
11.2.2. Relationship of Events to Study Treatment
The following definitions should be considered when evaluating the relationship of AEs and 
SAEs to the study  treatment.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
55The Investigator will assess all AEs regarding any causal relationship to the study  treatment (see
Section 11.2.2), the severity  of the event, action taken, and subject outcome.
The criteria set out in Section 11.2.[ADDRESS_309065] to follow -up.
For clinical stud y safet y reporting purposes, the version of the Investigator ’s Brochure at the 
time of the event occurrence will be used as the reference document to designate event 
expectedness.
Withdrawal from the study  as a result of an AE and any  therapeutic measures that are taken shall 
be at the discretion of the Investigator . If a subject withdraws from the study  for any  reason, any 
ongoing AEs will be followed until resolution, until deemed stable b y the Investigator , or until 
the subject is deemed b y the Investigator to be lost to follow -up.
11.3.2. Serious Adverse Events
Any SAE experienced by [CONTACT_254117] y follow -up visit (Visit 16) is to be recorded on an SAE form, regardless 
of the severit y of the event or its relationship to study treatment. SAEs must be reported to the 
Sponsor within [ADDRESS_309066] swill be followed for all SAEs until the completion of the safet y follow -up visit 
(Visit
16). Thereafter, the event should be reported to the Sponsor only if the Investigator
considers the SAE to be related to study  treatment.
Any SAE that is ongoing when the subject completes or discontinues the study  will be followed 
by [CONTACT_71390], stabilized, or returned to baseline status.
11.3.3. Immediate Reporting of Serious Adverse Events
In order to adhere to all applicable laws and regulations for reporting an SAE, the study  site must 
formally  notify  the Sponsor within 24 hours of the site staff becoming aware of the SAE. It is th e 
Investigator ’s responsibility  to ensure that the SAE reporting information and procedures are 
used and followed appropriately .
Protocol ALK8700 -A301, Version 5.[ADDRESS_309067] according to the protocol. Overdoses are not considered 
AEs and should not be recorded as an AE on the eCRF; however, all overdoses must be recorded 
on an Overdose form and faxed or emailed to the Sponsor within [ADDRESS_309068] be recorded on the do sing 
eCRF.
11.4.3. Medical Emergency
In a medical emergency  requiring immediate attention, site staff will apply  appropriate medical 
intervention, according to current standards of care. The Investigator (or designee) should 
contact [CONTACT_43038] y’s Medical Director. R efer to the Study  Reference Manual ’s Official Stud y 
Contact L ist for complete contact [CONTACT_3031].
11.5. Contraception Requirements
All male and female subject s must agree to the use of [ADDRESS_309069] 1 
form of highly  effective method of contraception and 1 acceptable method of contraception (and 
additional restrictions, if required, will be clarified in the locally  approved ICF). Subject
s who 
areabstinent are eligible, provided they  agree to the use of 2 contraceptive methods (at least 
1being a highl y effective method) should they  become sexually  active.
Highly effective methods may include:
Oral, intravaginal, or transdermal combined (estrogen 
and progestogen containing) 
hormonal contraception associated with inhibition of ovulation (oral contraceptives 
must have been initiated at least 30 days prior to screening)
Oral, injectable, or implantable progestogen -only hormonal contraception associated 
with inhibition of ovulation (oral contraceptives must have been initiated at least 
30days prior to screening)
Intrauterine device
Intrauterine hormone -releasing s ystem
Bilateral tubal occlusion
Vasectomized partner (provided that partner is sole sexual partner of subject and 
partner has received medical assessment of surgical success)
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
58Sexual abstinence (defined as refraining from heterosexual intercourse during the 
entire study  period through at least 30 day s after the final dose of study  treatment )
Acceptable methods may include:
Double- barrier protection (e .g., male condom, female condom, cervical cap or 
contraceptive sponge with spermicide, or a diaphragm with spermicide)
Subject s who are surgically  sterile are exempt from the requirement to use contr aception. 
Women who have undergone a documented complete hy sterectomy , bilateral tubal ligation, or 
bilateral salpi[INVESTIGATOR_8936] -oophorectomy  at least [ADDRESS_309070] 
fill out a Pregnancy  Report Form and submit the information to the S ponsor within 24 hours of 
awareness of the pregnancy , irrespective of wh ether an AEhas occurred. The ET 
and safet y 
follow -up visits will be scheduled.
The Investigator will follow the pregnancy  until completion or until pregnancy  termination and 
notify  the outcome to the Sponsor. I f the outcome of the pregnancy  meets the crit eria for 
immediate classification as an SAE the Investigator should follow the procedure of reporting 
SAEs (see Section 11.3.3 ). Additional follow -up may  be required.
Pregnancy  reporting is described in Section 11.4.1 .
11.6. Safety Responsibilities
11.6.1. The Investiga
tor
The Investigator ’s responsibilities include the following:
Monitor and record all AEs, including SAEs, on the eCRF regardless of the severit y 
or relationship to study  treatment.
Determine the seriousness, relationship, and severity  of each event.
Deter mine the onset and resolution dates of each event.
Monitor and record all pregnancies and follow up on the outcome of all pregnancies.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
59Complete an SAE form for each SAE and fax or email it to the Sponsor within 
24hours of the site staff becoming aware of the event.
Pursue SAE follow- up information activel y and persistently. Follow -up information 
must be reported to the Sponsor within 24 hours of the site staff becoming aware of 
new information.
Ensure all AE and SAE reports are supported b y documentation i n the subject s’ 
medical records.
Pursue AE follow -up information, if possible, until the event has resolved or become 
stable. Record AE follow-up information, including resolution, on the e CRF, as 
applicable.
Report SAEs to local ethics committees, as requ ired by  [CONTACT_1769].
11.6.2. The Sponsor
The Sponsor’s responsibilities include the following:
Before a site can enroll any  subject s, the Clinical Monitor (or designee) is responsible 
for reviewing with site staff the definitions of AE and SAE, as well as the instru ctions 
for monitoring, recording, and reporting AEs and SAEs.
The Sponsor is to notify  all appropriate regulatory authorities, central ethics 
committees, and Investigator s of SAEs, as required by  [CONTACT_1769], within required time 
frames.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
6012. STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
The objectives of the study  and the endpoints to be anal yzed are listed in Section 4.
12.1. General Considerations
The statistical anal ysis methods are described below. Additional details will be provided in the 
Statistical Analy sis Plan.
In general, summary  statistics (number of subject s, mean, standard deviation, median, minimum ,
and maximum values for continuous variables, and number and percentage of subject s in each 
category  for categorical variables) will be provided for all parameters. All statistical results will 
be presented based on observed values. All individual subject level data will be presented as data 
listings.
12.2. Analysis Sets
12.2.1. Safety Population
The safet y population, defined as all enrolled subject s who receive at le ast [ADDRESS_309071] over time will be anal yzed using 
data from the full anal ysis set (FAS), defined as all subject s who receive at l east [ADDRESS_309072] over time will be based on data from the FAS population.
All endpoints listed below will be summarized by [CONTACT_254118].
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
61Clinical endpoints
ARR
Proportion of subjec ts experiencing a relapse
EDSS score
T25- FW score
Proportion of subject s with No Evidence of Disease Activity (NEDA) at Week 96
Other endpoints
SF-12 (domain score)
EQ-5D- 5L VAS scores
The ARR will be summarized as number of relapses per subject per y ear, 
in which subject study  
duration is calculated as the time from first dose to last dose of study  medication +1. NEDA will 
indicate an absence of select clinical (MS relapse and disease progression)  
outcomes.
12.5. Methods of Analysis for Pharmacokinetic Endpoints
PK analy ses will be performed using the PK population. I ndividual plasma concentrations will 
be listed by  [CONTACT_254119]. Plots of individual and mean concentrations over time will also be generated. PK 
parameters will be calculated using noncompartmental anal ysis. Parameters will be estimated 
using actual elapsed time from dosing and summarized using descriptive statisti cs. A subject
listing of individual PK parameters will be provided.
Additionally , PK concentration data obtained from this study  will may  be combined with data 
from other studies to develop a population PK model, which will be reported separatel y.

Protocol ALK8700 -A301, Version 5.[ADDRESS_309073] swith 
RRMS, taking into account International Council for Harmonisation ( ICH)guidance on the 
extent of patient exposures required to assess clinical safety for a new drug.
Protocol ALK8700 -A301, Version 5.[ADDRESS_309074] . In this case, the appropriate regulatory  authorities will be notified subsequent 
to the modification.
In the event of a protocol modification, the I CF may  require similar modifications (see 
Section 13.4).
13.4. Informed Consent
Prior to performing an y study-
related activities under this protocol, including screening tests and 
assessments, informed consent with the approved ICF must be obtained.
A cop y of the signed and dated ICF and assent must be given to the subject and/or the subject ’s 
legally  authorized representative. The original signed and dated I CF will be retained with the 
study  records. Local regulations must be complied with in respect to the final disposition of the 
original and copi[INVESTIGATOR_71323].
Confirmation of informed consent and assent must also be documented in the subject ’s medical 
record.
When additional information that may  affect subject s’willingness to continue in the study  
becomes available, the Investigator s will be notified in a timely  manner , according to all local 
and applicable law. An updated ICF may  be required.
13.5. Confirmation of Willingness to Continue in the Study
Written documentation of a subject ’s willingness to continue participation in the study  will be 
required if one or more of the following occurs during the stud y:
MS relapse
Disability  progression (based on EDSS)
Protocol ALK8700 -A301, Version 5.[ADDRESS_309075] (e.g., financial interest in the 
Sponsor or its partnering compan y) with the subject before the subject make s a decision to 
participate in the stud y.
13.9. Study Report Signatory
The Sponsor will designate one or more of the participating Investigator s as a signatory  for the 
study  report. This determination will be made by  [CONTACT_71411], including but not limited to , the 
Investigator 's experience and reputation in the studied indication; the Investigator 's contribution 
to the study  in terms of design, management, and/or subject enrollment; or by  [CONTACT_254120] .
The Sponsor willfollow all applicable local regulations pertaining to stud y report signatories.
13.10. Registration of Study and Disclosure of Study Results
The Sponsor 
will register the study  and post study  results regardless of outcome on a publicly  
accessible website in acco rdance with the applicable laws and regulations.
The Sponsor also will notify , when required, the regulatory  authorities and ethics committees 
about the completion or termination of this study  and send a cop y of the study s ynopsis in 
accordance with necess ary timelines.
13.11. Retention of Study Data
Retention and storage of all essential clinical study documents shall be governed b y the terms 
and conditions of the site’s Clinical Study  Agreement ( CSA )and in accordance with ICH 
guidelines/local regulatory require ments as follows:
Essential documents should be retained until at least [ADDRESS_309076]. These documents should be retained for a 
longer period, however, if required b y the applicable regulatory requirements or by  [CONTACT_254121]. I t is th e responsibility  of the 
Sponsor to inform the Investigator /institution as to when 
these documents no longer need to be retained. Prior to proceeding with destruction of records, 
the Investigator must notify  the Sponsor in writing and receive written author ization from the 
Sponsor to destroy  study  records. In addition, the Investigator must notify  the Sponsor of any  
changes in the archival arrangements including but not limited to archival at an offsite facility  or 
transfer of ownership if the Investigator leaves the site .
Subject s’ medical files should be retained in accordance with the applicable legislation and in 
accordance with the maximum period of time permitted by  [CONTACT_5035][INVESTIGATOR_307], institution, or private 
practice.
Protocol ALK8700 -A301, Version 5.[ADDRESS_309077] been processed correctly. Data anomalies will be communicated to the 
sites for clarification and resolution, as appropriate. The Investigator is responsible for endorsing 
all 
eCRF data prior to any  interim or final database lock.
During and/or after completion of the study , quality  assurance officers named by  [CONTACT_254122]. The Investigator will 
be expected to cooperate with any  audit or inspection and to provide assistance and 
documentation (including source data) as requested.
15.3. Case Report Forms
This study  will use eCRFs. All eCRF data must be based on source documents or approved to be 
the original data (i.e., data directl y reported on the eCRF). All eCRFs will be completed b y the 
clinic staff prior to review by [CONTACT_254123].
The Biogen monitor or des ignated representative will review all source records on -site and 
compare them to the data collected on the eCRF.
15.4. Confidentiality of Data
By [CONTACT_12570], the Investigator affirms to Biogen that he or she will maintain in 
confidence information fu rnished to him or her b y Biogen and will divulge such information to 
his or her respective IRB or ethics committee under an appropriate understanding of 
confidentiality  with such board. All data will be considered the sole property  of Biogen. Please 
refer to the CSA for details.
Protocol ALK8700 -A301, Version 5.[ADDRESS_309078] s’ medical histories. Source data must be attributable, legible, 
contemporaneous, original, ac curate, and complete. Changes to source data must be traceable, 
not obscure the original entry , and be explained if necessary  (e.g., with an audit trail). The 
Investigator should maintain a record of the location(s) of essential documents.
The Biogen monit or or designee will visit the study  site at regular intervals during the study  and 
after the stud yhas completed, as appropriate. A clinical site monitoring plan will detail who 
performs the monitoring, how often, and the extent of review. It also will pro vide the monitoring 
strategy , with emphasis on subject safet y, data integrit y, and critical data and processes.
During these visits, eCRF s, supporting documentation, and essential documentation related to the 
study  will be reviewed and any  discrepancies or omissions will be resolved. Documentation of 
results will be provided to the Sponsor in a timely fashion to allow follow -up and verification of 
compliance with the monitoring plan. Remote evaluation of data (centralized monitoring) may  
also be conducted a nd reported as 
defined in the monitoring plan.
Monitoring visits must be conducted according to the applicable ICH and GCP guidelines to 
ensure the protection of subject rights and well -being, protocol adherence, quality  of data 
(accurate, complete, and ve rifiable), stud y treatment accountability, compliance with regulatory 
requirements, and continued adequacy  of the investigational site and its facilities.
15.6. Audits and Inspections
By [CONTACT_12142], the Investigator agrees that, within local regulatory restrictions and 
institutional and ethical considerations, authorized representatives of Biogen, a regulatory  
authority , and/or an IRB/ ethics committee may visit the site to perform audits or inspections, 
including the drug storage area, study  treatment stocks, drug accountability records, subject
charts and source documents, and other records relative to study  conduct. The purpose of a 
Biogen audit or inspection is to sy stematicall y and independentl y examine all study -related 
activities and documents (e.g., laboratory  reports, x -rays, workbooks, subject s’ medical records) 
to determine whether these activities were conducted, and data recorded, analy zed, and 
accuratel y reported according to the protocol, GCP guidelines of the ICH, and an y applicable 
regulat ory requirements.
The Investigator should contact [CONTACT_254124] b y a regulatory agency  
regarding an inspection.
15.7. Study Funding
Biogen is the Sponsor of the study  and is funding the study . All financial details are provided in 
the separate 
contracts between the institution, I nvestigator, and Biogen.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
7015.8. Publications
Details are included in the clinical trial agreement for this study .
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
7116. REFERENCES
Calabresi PA, Kieseier BC, Arnold DL , et al. Pegy lated interferon beta -1a for rel apsing -remitting 
multiple sclerosis (ADVANCE): a randomised, phase 3, double- blind study . Lancet Neurol. 
2014;13(7):657 -65. Epub 2014 Apr 30.
Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing 
therapeutics for pe diatric multiple sclerosis. Mult Scler. 2012;18(1):116- 27.
Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β -1a at 5- year 
follow -up of CAMMS223 clinical trial. Neurology . 2012;78(14):1069 -78.
Costello K, Halper J, Kalb R, et al. The use of disease -modify ing therapi[INVESTIGATOR_254100]: 
principles and current evidence. Multiple Sclerosis Coalition; 2014.
FDA. Tecfidera - Summary  Review. 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000SumR.pdf .
Fox RJ, Miller DH, Phillips JT, et al. Placebo- controlled phase 3 stud y of oral BG -12 or 
glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087 -97. Erratum in: N Engl J 
Med. [ADDRESS_309079] 25;367(17):1673.
Gold R, Kappos L , Arnold DL , et al. Placebo- controlled phase 3 study  of oral BG -12 for 
relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-107.
Jacobs L D, Cookfair DL, Rudick RA, et al. I ntramuscula r interferon beta -1a for disease 
progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group 
(MSCRG). Ann Neurol. 1996;39(3):285-94.
Johnson KP, Brooks BR, Cohen JA, et al. Copoly mer 1 reduces relapse rate and improves
disability  in relapsing -remitting multiple sclerosis: results of a phase III multicenter, double -
blind placebo -controlled trial. The Copoly mer 1 Multiple Sclerosis Study  Group. Neurology . 
1995;45(7):1268 -76.
Kappos L, Gold R, Miller DH, et al. Efficacy  and safet y of oral fumarate in patients with 
relapsing -remitting multiple sclerosis: a multicentre, randomised, double- blind, placebo -
controlled phase IIb study. Lancet. 2008;372(9648):1463 -
72.
Kappos L, Radue EW, O'Connor P, et al. A placebo- controlled tr ial of oral fingolimod in 
relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387
-401. Epub 2010 Jan 20.
Kaufman M, Mo yer D, Norton J. The significant change for the Timed 25- foot Walk in the 
multiple sclerosis functional composite. Mult Scler. 2000;6 (4):286- 90. Epub 2000/08/30.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
72Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability  status 
scale (EDSS). Neurology. 1983;33(11):1444- 52. Epub 1983 Nov 01.
Levey  AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. 
Ann Intern Med. 2009;150(9):604 -12.
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an 
international survey. National Mul tiple Sclerosis Society  ([LOCATION_003]) Advisory  Committee on Clinical 
Trials of New Agents in Multiple Sclerosis. Neurology . 1996;46(4):907 -11.
Maruish MEE. User's manual for the SF -12v2 Health Survey. 3rd ed. L incoln, RI : 
Quality Metric, Incorporated; 2012.
O'Con nor P, Wolinsky  JS, Confavreux C, et al. Randomized trial of oral teriflunomide for 
relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-303.
Phillips JT, Fox RJ. BG -12 in multiple sclerosis. Semin Neurol. 2013;33(1):56- 65. Epub 
2013/05/25.
Phillips JT, Hutchinson M, Fox R, et al. Managing flushing and gastrointestinal events 
associated with delay ed-release dimeth yl fumarate: Experiences of an international panel. 
Multiple Sclerosis and Related Disorders. 2014.
Polman CH, O'Connor PW, Havrdova E , et al. A randomized, placebo -controlled trial of 
natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899 -910.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 
revisions to the McDonald criter ia. Ann Neurol. 2011;69(2):292 -302.
Posner K, Brown GK, Stanley  B, et al. The Columbia -Suicide Severit y Rating Scale: initial 
validity  and internal consistency  findings from three multisite studies with adolescents and 
adults. Am J Psy chiatry . 2011;168(12 ):1266-77.
PRISMS Study  Group. Randomised double -blind placebo -controlled study  of interferon beta -1a 
in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498 -504.
Ropper AH. The "poison chair" treatment for multiple sclerosis. N Engl J Med . 
2012;367(12):1149 -50.
Tecfidera®Summary  of Product Characteristics, Nov 2017, Biogen Idec Inc.
The IFNB Multiple Sclerosis Study  Group. Interferon beta -1b is effective in relapsing -remitting 
multiple sclerosis. I . Clinical results of a multicenter, ra ndomized, double -blind, placebo -
controlled trial. Neurology. 1993;43(4):655 -61.
Protocol ALK8700 -A301, Version 5.0
Long -Term  Safety and Tolerability o f ALKS 8700 in Adults With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
73Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history  of multiple 
sclerosis. Neurology. 2010;74(24):2004-15.
Utz KS, Hoog J, Wentrup A, et al. Patie nt preferences for disease -modify ing drugs in multiple 
sclerosis therap y: a choice -based conjoint anal ysis. Ther Adv Neurol Disord. 2014;7(6):263-75.
Waldman AT, Gorman MP, Rensel MR, et al. Management of pediatric central nervous s ystem 
demy elinating disorders: consensus of [LOCATION_002] neurologists. J Child Neurol. 
2011;26(6):[ADDRESS_309080] read the foregoing protocol, “ APhase 3 Open Label Study  to Evaluate the L ong-Term 
Safety  and Tolerability  of ALKS 8700 in A dults With Relapsing Remitting Multiple Sclerosis ”
and agree to conduct the study  according to the protocol and the applicable I CH guidelines and 
GCP regulations, and to inform all who assist me in the conduct of this study of their 
responsibilities and obligations.
____________________________________________________
Investigator ’s Signature [CONTACT_1782]
____________________________________________________
Investigator ’s Name (Print)
____________________________________________________
Study  Site (Print )
 
SUMMARY OF CHANGES   
Protocol Amendment 3.0 
 
 Study number : ALKS  8700 A301  
Study title: A Phase 3 Open Label Study to Evaluate the Long- term Safety and 
Tolerability of ALKS  8700 in Adults with Relapsing Remitting Multiple Sclerosis   
Amendment date: 26 Jun 2019 
 
  
  
Sponsor: Alkermes, Inc.  
[ADDRESS_309081] 
Waltham, MA [ZIP_CODE] Telephone: +[PHONE_5282] 
 
 
 
CONFIDENTIAL  
Information and data in this protocol contain trade secrets and privileged or confidential 
information, which is the property of the Sponsor. No person is authorized to make it public 
without the written permission of the Sponsor. These restrictions or disclosures will apply 
equally to all future information supplied to you that is indicated as privileged or confidential. 
ALK8700-A301 | Protocol Amend_V3.0_Summary of Change_21Jun2019 | VV-TMF-452303 | 1.[ADDRESS_309082] 2019
  Alkermes, Inc.  
Protocol ALK8700-A301 (Amendment 3.0) CONFIDENTIAL  
 
Page [ADDRESS_309083] of the 
study, namely that all events of multiple sclerosis ( MS) relapse are being recorded as adverse 
events ( AEs). In addition, sample size numbers were made more flexible, sections were revised 
to allow better clarity of procedures, and last subject last visit date was revised to allow for additional rollover subjects from Study A302. The major changes are listed below: 
• Clarify language around MS relapse collection as an adverse event  
• Update sample size to approximately 1000 
• Clarify timing of disease -modifying therapy ( DMT ) allowance  
• Clarification to the lymphocyte monitoring section  
• Clarification of serious adverse event reporting 
• Update to S chedule of Assessments table  
 
• Update de novo pharmacokinetic ( PK) sample size  
• Update estimated last subject last visit ( LSLV ) 
• Administrative changes to contact [CONTACT_3031], and clarifying languag e was also 
provided. 
Additional changes such as updates to the title page, the Table of Contents, List of Abbreviations, and headers/footers (to reflect the new document version and date) have been made. Corrections for grammatical and other minor consiste ncy errors have also been made 
throughout the protocol . These changes are not described here. ALK8700-A301 | Protocol Amend_V3.0_Summary of Change_21Jun2019 | VV-TMF-452303 | 1.[ADDRESS_309084] 2019

  Alkermes, Inc.  
Protocol ALK8700-A301 (Amendment 3.0) CONFIDENTIAL  
 
Page 3 of 5 
 2. OVERVIEW OF CHANGES 
Content Changes  
1. Change: Clarify language around MS relapse collection as an adverse event 
Description of Change :  
In Section 8.2.2, bullet [ADDRESS_309085]’s willingness to continue in the 
study.  
In Section 8.2.12, language was added to clarify that efficacy analyses related to MS relapse 
include only events of protocol- defined relapse.  In addition, language was added to clarify 
the bulleted list of neurological symptoms.  
In Section 11.1, the following language was added to clarify the collection of AEs and SAEs 
for disability progression based on the EDSS and MS relapse: Disability progression based on 
the EDSS is captured in the MS efficacy assessments and is not to be recorded as an AE 
unless the event meets the definition of an SAE (see Section 11.2) Events o f MS relapse, 
whether protocol -defined or not, are to be recorded as AEs (or as SAEs [see Section 
11.2]). and/or relapse of MS will be captured in the MS efficacy assessments, and not recorded 
as an AE, unless they meet the definition for an SAE see Section 11.2. 
Rationale for Change:  Language in the protocol is being updated to reflect what is being practiced in the conduct of the study, namely that all events of MS relapse are being recorded 
as AEs.   
Sections Impacted:  Section 8.2.2 (Bullet 1); Section 8.2.12 (first sentence and last 3 bullets); 
Section  11.1 
2. Change: Update sample size to approximately 1000 
Description of Change: Expected sample size for the study was increased from 800 to 
approximately 1000.  
Rationale for Change: With increased sample s ize and enrollment for the ALK8700-A302 
study, more subjects have consequently rolled over to the ALK8700-A301 study. Accordingly, the estimated sample size for the ALK8700 -A301 study is being updated. In addition, the 
rollover rate from study A302 was hig her than expected (90%) which increased the sample 
size for A301.  
Sections Impacted:  Section 2 : Synopsis (Number of Subjects Planned, Sample Size 
Considerations ); Section 14.1 ALK8700-A301 | Protocol Amend_V3.0_Summary of Change_21Jun2019 | VV-TMF-452303 | 1.[ADDRESS_309086] 2019
  Alkermes, Inc.  
Protocol ALK8700-A301 (Amendment 3.0) CONFIDENTIAL  
 
Page 5 of 5 
 Content Changes  
7. Change: Update de novo PK sample size  
Description of Change:  The subset of de novo subjects that will contribute to the plasma 
samples for concentrations of ALKS 8700 analytes (eg, MMF, RDC-6567, and RDC-8439) 
considered appropriate for further evaluation was updated from n=50 to approximately 50. 
Rationale for Change:  The language was updated to provide appropriate flexibility for the 
sample number. 
Sections Impacted:  Section 2 : Synopsis (Pharmacokinetics) and Section 13. 
8. Change: Update estimated LSLV  
Description of Change:  The estimated date of last subject’s last visit was updated from Q4 
2019 to Q3 2021. Rationale for Change: A302 German subjects will be rolled over into A301 (2 year) study 
which will push back the A301 LPLV in Q4 2020 or somewhere in 2021. Q3 2021 was agreed by [INVESTIGATOR_19316].  
Sections Impacted : Section 2 : Synopsis (Study Period) 
 
Administrative/Editorial Changes (Deleted text is indicated as strikethrough and new text 
as bold face)  
1. Update  medical director  
 was updated to , MD, FAASM. Address and phone 
numbers were also updated. 
2. Addition of Alkermes Global Safety Officer 
 was added to Table [ADDRESS_309087] Information as the Alkermes Global 
Safety Officer  
3. Update  to  
All instances of  in the protoc ol were updated to . This included 
Section [IP_ADDRESS], Table [ADDRESS_309088] Information, Section 11.5. 
4. Updated language for version of IB to be used as reference for “expectedness” of AE.  
In Section 11.4, the following sentence was updated: For clinical safety reporting purposes, the 
most recent  version of the Investigator’s Brochure at the time of the event occurrence will 
be used as the reference document to designate event expectedness.  
 ALK8700-A301 | Protocol Amend_V3.0_Summary of Change_21Jun2019 | VV-TMF-452303 | 1.[ADDRESS_309089] 2019
